Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Nucleosides Stories

2014-04-07 08:30:00

Phase I Demonstrates Quizartinib Tolerability in Combination with Chemotherapy SAN DIEGO, April 7, 2014 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose...

2014-04-03 12:29:29

Poor Efficacy and Physicians' Desire for Personalized Therapeutics Will Provide Opportunity for Developers of New Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that azacitidine (Celgene's Vidaza, generics) will continue to be the patient share leader in treatment of myelodysplastic syndromes (MDS) in the United States and major European markets during the 2013-2023 study period. According to...

2014-03-26 08:23:02

DUBLIN, Mar. 26, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/pt8tl4/treating ) has announced the addition of the "Concise Analysis of New Methods for Treating Refractory Hematological Malignancies - Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Targeting unmet needs in the treatment of cancer through innovative drug development strategies have...

2013-12-24 13:31:09

The drug inosine appears to be a safe and effective way to raise blood and cerebrospinal fluid urate levels in patients with early Parkinson disease (PD), suggesting it may be a potential strategy to slow the disability progression of the degenerative neurological disorder, according to a report published by JAMA Neurology, a JAMA Network publication. Urate is an end product of human metabolism. Animal experiments suggest that urate may protect against PD, and higher blood urate levels are...

2013-12-09 12:26:23

First patients dosed in Phase 2 dose confirmation trial SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data at the 2013 American Society of Hematology (ASH) Annual Meeting demonstrating promising clinical response rates in patients with myelodysplastic syndromes (MDS) patients treated with mocetinostat in combination with azacitidine. Separately, Mirati announced that it has dosed the first patients in its Phase 2 dose...

2013-11-08 08:27:34

SAN DIEGO, Nov. 8, 2013 /PRNewswire/ -- Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today announced that it will be presenting Phase 1/2 data on mocetinostat in myelodysplastic syndromes (MDS) at the 55(th) American Society of Hematology Annual Meeting taking place December 7-10 in New Orleans. Data to be presented demonstrates promising clinical responses to the combination of mocetinostat, a novel spectrum selective HDAC inhibitor, with azacitidine (marketed as Vidaza® by...

2013-08-01 08:35:47

Live Webcast from New York on Tuesday, August 13 SAN DIEGO, Aug. 1, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Wedbush Life Sciences Management Access Conference on Tuesday, August 13, 2013 at 2:30 p.m. Eastern time from Le Parker Meridien in New York City. A live webcast of the...

2013-07-19 08:26:46

NEW YORK, July 19, 2013 /PRNewswire/ -- Royalty Pharma is pleased to announce that Marshall Urist, MD, PhD, has joined the company as Vice President, Research and Investments. Dr. Urist spent the last eight years at Morgan Stanley in equity research, most recently as Executive Director and the senior biotechnology analyst. Earlier at Morgan Stanley, he covered the life science tools and diagnostics sectors, where he was recognized in Institutional Investor's All-America Research...

2013-05-29 08:31:57

Live Webcast from New York on Thursday, June 6 SAN DIEGO, May 29, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference on Thursday, June 6, 2013 at 8:30 a.m. Eastern time from the Grand Hyatt in New York City. A live webcast of the presentation can be...

2013-04-23 08:35:06

Live Webcast from New York on Tuesday, April 30 SAN DIEGO, April 23, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Needham Healthcare Conference on Tuesday, April 30, 2013 at 2:20 p.m. Eastern time from the Westin Grand Central Hotel in New York City. A live webcast of the presentation can...